Squarepoint
RANI icon

Squarepoint’s Rani Therapeutics RANI Stock Holding History

Squarepoint’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.9K Buy
41,902
+25,501
+155% +$22.6K ﹤0.01% 4293
2026
Q1 		$12.1K Sell
16,401
-327,977
-95% -$419K ﹤0.01% 4184
2025
Q4 		$465K Buy
+344,378
New +$520K ﹤0.01% 3271
2025
Q1 		– Sell
-10,863
Closed -$14.9K – 5252
2024
Q4 		$14.9K Buy
+10,863
New +$22.8K ﹤0.01% 4949
2022
Q1 		– Sell
-50,000
Closed -$818K – 3390
2021
Q4 		$818K Hold
50,000
– – ﹤0.01% 1824
2021
Q3 		$891K Buy
+50,000
New +$865K ﹤0.01% 1627

Other funds holding RANI

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Squarepoint's RANI Position: Q2 2026 in Review

Squarepoint increased its Rani Therapeutics (RANI) stake by 155% in Q2 2026, buying an estimated $22.6K and bringing the position to 41,902 shares worth $31.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4293.

Squarepoint first reported a position in RANI in Q3 2021 and has held it in 6 quarters since. The position peaked at $891K in Q3 2021. 68 funds tracked by Wall St. Rank hold RANI as of Q2 2026.

  • Squarepoint held 41,902 shares of Rani Therapeutics worth $31.9K as of Q2 2026.
  • Squarepoint bought 25,501 Rani Therapeutics shares in Q2 2026, an estimated $22.6K.
  • Rani Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #4293 holding.
  • Squarepoint first reported a position in Rani Therapeutics in Q3 2021 and has held it in 6 quarters since.
  • Squarepoint's Rani Therapeutics position peaked at $891K in Q3 2021.
  • 68 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.